MIM
WHWK

MetLife Investment Management’s Whitehawk Therapeutics WHWK Stock Holding History

MetLife Investment Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-8,693
Closed -$59.5K – 2992
2023
Q2 		$59.5K Buy
+8,693
New +$67.6K ﹤0.01% 2882
2023
Q1 		– Sell
-7,671
Closed -$98.4K – 2818
2022
Q4 		$98.4K Buy
+7,671
New +$100K ﹤0.01% 2599
2022
Q3 		– Sell
-7,802
Closed -$96.1K – 2849
2022
Q2 		$96.1K Buy
+7,802
New +$116K ﹤0.01% 2727

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MetLife Investment Management's WHWK Position: Q3 2023 in Review

MetLife Investment Management sold out of Whitehawk Therapeutics (WHWK) in Q3 2023, closing a stake of 8,693 shares — an estimated $59.5K sold.

MetLife Investment Management first reported a position in WHWK in Q2 2022 and held it in 3 quarters. The position peaked at $98.4K in Q4 2022. 73 funds tracked by Wall St. Rank hold WHWK as of Q3 2023.

  • MetLife Investment Management reported no remaining Whitehawk Therapeutics position as of Q3 2023 after selling out during the quarter.
  • MetLife Investment Management sold 8,693 Whitehawk Therapeutics shares in Q3 2023, an estimated $59.5K.
  • MetLife Investment Management first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 3 quarters.
  • MetLife Investment Management's Whitehawk Therapeutics position peaked at $98.4K in Q4 2022.
  • 73 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2023.

Based on MetLife Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.